CEACAM5 and pancreatic adenocarcinoma: The current, retrospective, multicenter study investigated the association of serum CEA with overall survival (OS) among 277 patients with localized pancreatic adenocarcinoma who were treated with (m)FOLFIRINOX as initial treatment, having nonelevated (i.e., <37 U/ml) serum CA19-9 at baseline.4 In this subgroup, serum CEA was elevated in one-third of patients.